Ronan J Kelly1,2, Amir M Ansari3, Tomoharu Miyashita3, Marianna Zahurak4, Frank Lay3, A Karim Ahmed3, Louis J Born3, Maryam K Pezhouh5, Kevan J Salimian6, Christopher Ng3, Aerielle E Matsangos3, Anne-Heloise Stricker-Krongrad3, Ken-Ichi Mukaisho7, Guy P Marti3, Christine H Chung8, Marcia I Canto9, Michelle A Rudek10, Stephen J Meltzer9, John W Harmon3. 1. The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD. 2. Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX. 3. Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD. 4. Department of Oncology, Division of Biostatistics and Bioinformatics, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD. 5. Department of Pathology, Northwestern University School of Medicine, Chicago, IL. 6. Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD. 7. Department of Pathology, Shiga University of Medical Science, Shiga, Japan. 8. Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL. 9. Department of Medicine, Division of gastroenterology, The Johns Hopkins University School of Medicine. 10. Analytical Pharmacology Core, Department of Oncology, Department of Medicine/Division of Clinical Pharmacology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
OBJECTIVE: The aim of the study was to investigate whether inhibition of Sonic Hedgehog (SHH) pathway would prevent progression of Barrett's Esophagus (BE) to esophageal adenocarcinoma. BACKGROUND: The hedgehog signaling pathway is a leading candidate as a molecular mediator of BE and esophageal adenocarcinoma (EAC). Repurposed use of existing off-patent, safe and tolerable drugs that can inhibit hedgehog, such as itraconazole, could prevent progression of BE to EAC. METHODS: The efficacy of itraconazole was investigated using a surgical rat reflux model of Barrett's Metaplasia (BM). Weekly intraperitoneal injections of saline (control group) or itraconazole (treatment group; 200 mg/kg) were started at 24 weeks postsurgery. Esophageal tissue was harvested at 40 weeks. The role of the Hh pathway was also evaluated clinically. Esophageal tissue was harvested after 40 weeks for pathological examination and evaluation of the SHH pathway by immunohistochemistry. RESULTS: BM was present in control animals 29 of 31 (93%) versus itraconazole 22 of 24 (91%). EAC was significantly lower in itraconazole 2 of 24 (8%) versus control 10 of 31 (32%), respectively (P = 0.033). Esophageal SHH levels were lower in itraconazole vs control (P = 0.12). In esophageal tissue from humans with recurrent or persistent dysplastic BE within 24 months of ablative treatment, strong SHH and Indian Hedgehog expression occurred in distal BE versus proximal squamous epithelium, odds ratio = 6.1 (95% confidence interval: 1.6, 23.4) and odds ratio = 6.4 (95% confidence interval: 1.2, 32.8), respectively. CONCLUSION: Itraconazole significantly decreases EAC development and SHH expression in a preclinical animal model of BM. In humans, BE tissue expresses higher SHH, Indian Hedgehog, and bone morphogenic protein levels than normal squamous esophageal epithelium.
OBJECTIVE: The aim of the study was to investigate whether inhibition of Sonic Hedgehog (SHH) pathway would prevent progression of Barrett's Esophagus (BE) to esophageal adenocarcinoma. BACKGROUND: The hedgehog signaling pathway is a leading candidate as a molecular mediator of BE and esophageal adenocarcinoma (EAC). Repurposed use of existing off-patent, safe and tolerable drugs that can inhibit hedgehog, such as itraconazole, could prevent progression of BE to EAC. METHODS: The efficacy of itraconazole was investigated using a surgical rat reflux model of Barrett's Metaplasia (BM). Weekly intraperitoneal injections of saline (control group) or itraconazole (treatment group; 200 mg/kg) were started at 24 weeks postsurgery. Esophageal tissue was harvested at 40 weeks. The role of the Hh pathway was also evaluated clinically. Esophageal tissue was harvested after 40 weeks for pathological examination and evaluation of the SHH pathway by immunohistochemistry. RESULTS: BM was present in control animals 29 of 31 (93%) versus itraconazole 22 of 24 (91%). EAC was significantly lower in itraconazole 2 of 24 (8%) versus control 10 of 31 (32%), respectively (P = 0.033). Esophageal SHH levels were lower in itraconazole vs control (P = 0.12). In esophageal tissue from humans with recurrent or persistent dysplastic BE within 24 months of ablative treatment, strong SHH and Indian Hedgehog expression occurred in distal BE versus proximal squamous epithelium, odds ratio = 6.1 (95% confidence interval: 1.6, 23.4) and odds ratio = 6.4 (95% confidence interval: 1.2, 32.8), respectively. CONCLUSION: Itraconazole significantly decreases EAC development and SHH expression in a preclinical animal model of BM. In humans, BE tissue expresses higher SHH, Indian Hedgehog, and bone morphogenic protein levels than normal squamous esophageal epithelium.
Authors: Aleksandar Sekulic; Michael R Migden; Karl Lewis; John D Hainsworth; James A Solomon; Simon Yoo; Sarah T Arron; Philip A Friedlander; Ellen Marmur; Charles M Rudin; Anne Lynn S Chang; Luc Dirix; Jeannie Hou; Huibin Yue; Axel Hauschild Journal: J Am Acad Dermatol Date: 2015-06 Impact factor: 11.527
Authors: Tomoharu Miyashita; Furhawn A Shah; Guy P Marti; Jiaai Wang; Pramod Bonde; Michael K Gibson; Tetsuo Ohta; Elizabeth A Montgomery; Mark Duncan; John W Harmon Journal: Dig Dis Sci Date: 2010-10-30 Impact factor: 3.199
Authors: Navtej S Buttar; Kenneth K Wang; Olga Leontovich; Jay Y Westcott; Rodney J Pacifico; Marlys A Anderson; Krishnawatie K Krishnadath; Lori S Lutzke; Lawrence J Burgart Journal: Gastroenterology Date: 2002-04 Impact factor: 22.682
Authors: Luigi Mari; Francesca Milano; Kaushal Parikh; Danielle Straub; Vincent Everts; Kees K Hoeben; Paul Fockens; Navtej S Buttar; Kausilia K Krishnadath Journal: Cell Rep Date: 2014-05-01 Impact factor: 9.423
Authors: Pramod Bonde; Guoping Sui; Surajit Dhara; Jiaai Wang; Apoorv Broor; Irene F Kim; John E Wiley; Guy Marti; Mark Duncan; Elizabeth Jaffee; Elizabeth Montgomery; Anirban Maitra; John W Harmon Journal: J Thorac Cardiovasc Surg Date: 2007-03 Impact factor: 5.209
Authors: Emmanuel S Antonarakis; Elisabeth I Heath; David C Smith; Dana Rathkopf; Amanda L Blackford; Daniel C Danila; Serina King; Anja Frost; A Seun Ajiboye; Ming Zhao; Janet Mendonca; Sushant K Kachhap; Michelle A Rudek; Michael A Carducci Journal: Oncologist Date: 2013-01-22
Authors: Michael K Gibson; Ali H Zaidi; Jon M Davison; Alejandro F Sanz; Bruce Hough; Yoshihiro Komatsu; Juliann E Kosovec; Astha Bhatt; Usha Malhotra; Tyler Foxwell; Christina L Rotoloni; Toshitaka Hoppo; Blair A Jobe Journal: Ann Surg Date: 2013-07 Impact factor: 12.969
Authors: Wei Zhang; Ankur S Bhagwath; Zeeshan Ramzan; Taylor A Williams; Indhumathy Subramaniyan; Vindhya Edpuganti; Raja Reddy Kallem; Kerry B Dunbar; Peiguo Ding; Ke Gong; Samuel A Geurkink; Muhammad S Beg; James Kim; Qiuyang Zhang; Amyn A Habib; Sung-Hee Choi; Ritu Lapsiwala; Gayathri Bhagwath; Jonathan E Dowell; Shelby D Melton; Chunfa Jie; William C Putnam; Thai H Pham; David H Wang Journal: Mol Cancer Ther Date: 2021-08-10 Impact factor: 6.261
Authors: Christopher K Ng; Ke Ma; Yulan Cheng; Tomoharu Miyashita; John W Harmon; Stephen J Meltzer Journal: Transl Oncol Date: 2019-08-08 Impact factor: 4.243